RENB: Enochian BioSciences Price to Sales

Brandmark of Enochian BioSciences (RENB)

The development of AI platforms for cancer therapy involves high scientific risks and patent disputes for Renovaro Inc. (RENB). The P/S ratio visualizes the dynamics of market valuation relative to revenue, where serves as the base value of the parameter. The company's genetic potential provides stability through partnerships; however, the lack of operating leverage and high laboratory costs currently render the business unprofitable.

RENB (Renovaro Inc.) Price-to-Revenue Ratio history from 07/04/2022 to 11/15/2026

Analytical breakdowns for renovarobio.com (RENB)

- share price and consensus valuation forecast:
Price Performance Chart Renovaro|RENB - Analyst Consensus Forecast
- market capitalization information:
Market Value Renovaro|RENB - Total Company Value
- shareholders' equity book value data:
Equity per Share Renovaro|RENB - Company Book Value|Market-to-Book Ratio renovarobio.com|RENB - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Renovaro Inc.|RENB - Long-Term Debt to Capital|Short-Term Debt to Capital Renovaro Biosciences|RENB - Company Debts|Debt to Net Assets Ratio Renovaro|RENB - Company Long-Term Debt|Short-Term Debt Renovaro|Intermediate Coverage Ratio renovarobio.com
- net income and valuation multiples indicators:
RENB - Net Profit|Company Profit Forecast Renovaro Inc.|RENB - Price to Earnings Ratio|Price to Future Earnings Ratio Renovaro|RENB - PEG Multiple|Enterprise Value to EBITDA Ratio Renovaro Inc.|RENB - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Renovaro|RENB - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months renovarobio.com|RENB - Earnings growth in current year|Expected net earnings per share growth next year Renovaro Inc.
- total revenue and sales volume data:
RENB - Company Revenue|Company Revenue Forecast Renovaro|RENB - P/S Multiple|Price-to-Projected Revenue Ratio RENB
Fundamental company analysis:Renovaro Inc., RENB
Product sample of Renovaro Inc.

Evaluating the scale of Renovaro Inc. (RENB) via the P/S ratio compares market capitalization to annual sales volume. This price/sales metric measures the cost of one dollar of revenue, allowing for the determination of asset overvaluation. The price/sales trend captures market expectations regarding the commercialization of genetic developments. Intellectual capital in the field of cancer immunotherapy ensures business resilience, transforming current sales into a long-term foundation of value.

Competitors of Renovaro Inc.

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|URGN: P/S Multiple|Bicara Therapeutics Inc (BCAX) - P/S Multiple|Price-to-Revenue Ratio personalis.com|Market Cap to Revenue Erasca Corp (ERAS)|Market Cap to Revenue DCTH (Delcath)|Price-to-Revenue Coefficient Y-mAbs Therapeutics, Inc.|P/S Multiple AURA (Aura Biosciences Inc)|Market Capitalization-to-Revenue Ratio CADL|ARAY: Market Cap to Revenue|Price-to-Revenue Coefficient sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Market Cap to Revenue Ratio CTOR|Price-to-Revenue Ratio TuHURA Biosciences Inc.|TARA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Fate Therapeutics (FATE)|Price-to-Revenue Coefficient Aadi Bioscience|Price-to-Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Revenue Ratio|XBIT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CVM (cel-sci.com)|OSTX: P/S Multiple|Price to Sales Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - P/S Multiple|Market Cap to Revenue Ratio ANL (Adlai Nortye)|Price-to-Revenue Ratio Veru Pharma (VERU)|P/S Multiple Tempest Tx (TPST)|Price-to-Revenue Ratio xiliotx.com XLO|Mural Bio - Price-to-Revenue Ratio|KAPA - Price-to-Revenue Ratio|OnKure Therapeutics (OKUR) - Market Cap to Revenue|GDTC: P/S Multiple|Price to Sales Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S Multiple|Market Cap to Revenue Tharimmune Corp (THAR)|P/S Multiple ADVB|GNPX - Price to Sales|Price-to-Revenue Ratio calidibio.com CLDI|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd